Mark Verrill

3.9k total citations · 1 hit paper
85 papers, 2.4k citations indexed

About

Mark Verrill is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Mark Verrill has authored 85 papers receiving a total of 2.4k indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Oncology, 37 papers in Cancer Research and 32 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Mark Verrill's work include Breast Cancer Treatment Studies (36 papers), Cancer Treatment and Pharmacology (35 papers) and HER2/EGFR in Cancer Research (26 papers). Mark Verrill is often cited by papers focused on Breast Cancer Treatment Studies (36 papers), Cancer Treatment and Pharmacology (35 papers) and HER2/EGFR in Cancer Research (26 papers). Mark Verrill collaborates with scholars based in United Kingdom, United States and France. Mark Verrill's co-authors include Chris Plummer, Peter Canney, Alison Jones, Victoria Cornelius, Gill Levitt, L. A. Smith, Alan V. Boddy, Peter Barrett‐Lee, David Jamieson and Andrew Wardley and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Cancer Research.

In The Last Decade

Mark Verrill

81 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Cardiotoxicity of anthracycline agents for the treatment of cancer: Systematic review and meta-analysis of randomised controlled trials

2010 532 citations Chris Plummer, Mark Verrill et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Mark Verrill United Kingdom	23	1.3k	705	648	473	409	85	2.4k
Peter Canney United Kingdom	25	1.3k 0.9×	599 0.8×	472 0.7×	535 1.1×	359 0.9×	77	2.6k
Giuseppe Capri Italy	27	2.1k 1.5×	396 0.6×	453 0.7×	717 1.5×	555 1.4×	77	2.8k
Katherine H. R. Tkaczuk United States	21	1.8k 1.3×	300 0.4×	387 0.6×	968 2.0×	436 1.1×	47	2.8k
Susan Dent Canada	27	1.1k 0.8×	259 0.4×	313 0.5×	495 1.0×	315 0.8×	81	2.1k
Brendan Doyle Ireland	23	1.1k 0.8×	614 0.9×	638 1.0×	550 1.2×	1.5k 3.6×	56	3.5k
Erica L. Mayer United States	31	2.6k 1.9×	397 0.6×	997 1.5×	1.2k 2.5×	1.4k 3.4×	144	4.7k
Jacob C. Easaw Canada	24	437 0.3×	249 0.4×	623 1.0×	308 0.7×	598 1.5×	87	2.2k
Thomas Suter Switzerland	34	2.2k 1.6×	2.9k 4.1×	564 0.9×	331 0.7×	764 1.9×	78	4.4k
Pirkko‐Liisa Kellokumpu‐Lehtinen Finland	32	2.0k 1.5×	349 0.5×	875 1.4×	840 1.8×	767 1.9×	137	3.9k
Chau T. Dang United States	39	3.2k 2.4×	979 1.4×	1.3k 2.0×	1.4k 2.9×	839 2.1×	165	5.3k

Countries citing papers authored by Mark Verrill

Since Specialization

Citations

This map shows the geographic impact of Mark Verrill's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark Verrill with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark Verrill more than expected).

Fields of papers citing papers by Mark Verrill

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark Verrill. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark Verrill. The network helps show where Mark Verrill may publish in the future.

Co-authorship network of co-authors of Mark Verrill

This figure shows the co-authorship network connecting the top 25 collaborators of Mark Verrill. A scholar is included among the top collaborators of Mark Verrill based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark Verrill. Mark Verrill is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Velikova, Galina, James P. Morden, Joanne Haviland, et al.. (2023). Accelerated versus standard epirubicin followed by cyclophosphamide, methotrexate, and fluorouracil or capecitabine as adjuvant therapy for breast cancer (UK TACT2; CRUK/05/19): quality of life results from a multicentre, phase 3, open-label, randomised, controlled trial. The Lancet Oncology. 24(12). 1359–1374. 7 indexed citations

Maier, Rebecca, Chris Plummer, Adetayo Kasim, et al.. (2022). Preventing cardiotoxicity in patients with breast cancer and lymphoma: protocol for a multicentre randomised controlled trial (PROACT). BMJ Open. 12(12). e066252–e066252. 3 indexed citations

Dang, Chau T., Michael S. Ewer, Suzette Delaloge, et al.. (2022). BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. Cancers. 14(11). 2596–2596. 11 indexed citations

Dang, Chau T., Michael S. Ewer, Suzette Delaloge, et al.. (2021). 43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial. Annals of Oncology. 32. S38–S39. 3 indexed citations

Gennatas, Spyridon, Florence Chamberlain, Thomas Carter, et al.. (2020). Real-world experience with doxorubicin and olaratumab in soft tissue sarcomas in England and Northern Ireland. PubMed. 10(1). 9–9. 4 indexed citations

Verrill, Mark, et al.. (2017). Work Productivity in HER2 Positive Breast Cancer: A Comparison of Patients Across Stages of Early and Metastatic Disease. Value in Health. 20(9). A454–A454. 1 indexed citations

Jung, Kyung Hae, Beyhan Ataseven, Mark Verrill, et al.. (2016). Adjuvant subcutaneous trastuzumab for HER2-positive early breast cancer: Phase III SafeHer study subgroup analyses of body weights, active medical conditions, safety and tolerability. Annals of Oncology. 27. vi63–vi63. 1 indexed citations

Cresti, Nicola, Joanne Lee, Emma Rourke, et al.. (2016). Genetic variants in the HER2 gene: Influence on HER2 overexpression and loss of heterozygosity in breast cancer. European Journal of Cancer. 55. 27–37. 13 indexed citations

Jamieson, David, Nicola J. Sunter, Nicola Cresti, et al.. (2016). Pharmacogenetic association of MBL2 and CD95 polymorphisms with grade 3 infection following adjuvant therapy for breast cancer with doxorubicin and cyclophosphamide. European Journal of Cancer. 71. 15–24. 6 indexed citations

10.

Jamieson, David, Jo Lee, Nicola Cresti, et al.. (2014). Pharmacogenetics of adjuvant breast cancer treatment with cyclophosphamide, epirubicin and 5-fluorouracil. Cancer Chemotherapy and Pharmacology. 74(4). 667–674. 30 indexed citations

11.

Bulusu, V.R., John Fullarton, Michael Leahy, et al.. (2013). Rationale and design of a UK database for a rare cancer type: the GEM Registry for gastrointestinal stromal tumours. British Journal of Cancer. 109(6). 1403–1407. 5 indexed citations

12.

Horák, Jiří, Jeff White, Adrian L. Harris, et al.. (2011). The effect of different etiologies of hepatic impairment on the pharmacokinetics of gefitinib. Cancer Chemotherapy and Pharmacology. 68(6). 1485–1495. 25 indexed citations

13.

Jamieson, David, Nicola Cresti, Julieann Sludden, et al.. (2011). Two minor NQO1 and NQO2 alleles predict poor response of breast cancer patients to adjuvant doxorubicin and cyclophosphamide therapy. Pharmacogenetics and Genomics. 21(12). 808–819. 30 indexed citations

14.

Jones, Anna, Malcolm Barlow, Peter Barrett‐Lee, et al.. (2009). Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring. British Journal of Cancer. 100(5). 684–692. 147 indexed citations

15.

Poole, C. J., Louise Hiller, Helen Howard, et al.. (2006). Tolerability of gemcitabine in paclitaxel-containing, epirubicin/cyclophosphamide-based, adjuvant chemotherapy in the randomized phase III tAnGo trial for invasive higher risk early stage breast cancer.. Breast Cancer Research and Treatment. 100. 1 indexed citations

16.

Miller, William R., John M.S. Bartlett, Peter Canney, & Mark Verrill. (2006). Hormonal therapy for postmenopausal breast cancer: the science of sequencing. Breast Cancer Research and Treatment. 103(2). 149–160. 39 indexed citations

17.

Smith, Ian E., Roger A’Hern, Gill Coombes, et al.. (2005). Neoadjuvant vinorelbine/epirubicin (VE) versus standard adriamycin/cyclophosphamide (AC) in operable breast cancer: analysis of response and tolerability in a randomised phase III trial (TOPIC 2). Annals of Oncology. 16(9). 1435–1441. 31 indexed citations

18.

Hess, Viviane, et al.. (2003). Phase I study of carboplatin, doxorubicin and weekly paclitaxel in patients with advanced ovarian carcinoma. Annals of Oncology. 14(4). 638–642. 6 indexed citations

19.

Judson, Ian, Michael Leahy, Jeremy Whelan, et al.. (2002). A Guideline for the Management of Gastrointestinal Stromal Tumour (GIST). Sarcoma. 6(3). 83–87. 9 indexed citations

20.

Verrill, Mark, Ian Judson, E. Wiltshaw, et al.. (1997). The use of paediatric chemotherapy protocols at full dose is both a rational and feasible treatment strategy in adults with Ewing's family tumours. Annals of Oncology. 8(11). 1099–1105. 39 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact